Product Description
Linezolid is used to treat infections, including pneumonia, and infections of the skin . Linezolid is in a class of antibacterials called oxazolidinones. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a602004.html)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, Bulgaria, Chile, China, Croatia, Estonia, Georgia, Latvia, Philippines, Serbia, Slovakia, Spain, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Communicable Diseases|Diabetic Foot|Focal Infection
Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia|Tuberculosis, Multidrug-Resistant
Phase 1: Bacteremia|Community-Acquired Infections|Osteomyelitis|Pneumonia|Soft Tissue Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DRAMATIC | P2 |
Recruiting |
Tuberculosis, Multidrug-Resistant |
2027-05-01 |
|
| MRXC-302 | P3 |
Recruiting |
Communicable Diseases|Diabetic Foot|Focal Infection |
2026-06-30 |
|
| NCI-2021-01957 | P2 |
Completed |
Febrile Neutropenia|Acute Respiratory Distress Syndrome |
2023-10-06 |
|
| CTR20180890 | P1 |
Not yet recruiting |
Pneumonia|Osteomyelitis|Soft Tissue Infections|Community-Acquired Infections|Bacteremia|Diabetic Foot |
None |